Coherus Biosciences Inc (NASDAQ:CHRS) has a beta value of 0.82 and has seen 1.07 million shares traded in the recent trading session. The company, currently valued at $237.78M, closed the recent trade at $1.74 per share which meant it gained $0.08 on the day or 4.86% during that session. The CHRS stock price is -81.03% off its 52-week high price of $3.15 and 62.07% above the 52-week low of $0.66. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.34 million shares traded. The 3-month trading volume is 5.05 million shares.
The consensus among analysts is that Coherus Biosciences Inc (CHRS) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 5 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
Coherus Biosciences Inc (NASDAQ:CHRS) trade information
Sporting 4.86% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CHRS stock price touched $1.74 or saw a rise of 1.69%. Year-to-date, Coherus Biosciences Inc shares have moved 26.13%, while the 5-day performance has seen it change 16.82%. Over the past 30 days, the shares of Coherus Biosciences Inc (NASDAQ:CHRS) have changed 1.79%. Short interest in the company has seen 31.07 million shares shorted with days to cover at 3.23.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 71.0% from the levels at last check today. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the latest price level in today’s session is -244.83% off the targeted high while a plunge would see the stock gain -244.83% from the levels at last check today.
Coherus Biosciences Inc (CHRS) estimates and forecasts
Figures show that Coherus Biosciences Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 37.06% over the past 6 months, with this year growth rate of 64.65%, compared to 16.90% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 4.73% over the past 5 years.
CHRS Dividends
Coherus Biosciences Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Coherus Biosciences Inc (NASDAQ:CHRS)’s Major holders
Insiders own 1.38% of the company shares, while shares held by institutions stand at 70.28% with a share float percentage of 71.27%. Investors are also buoyed by the number of investors in a company, with Coherus Biosciences Inc having a total of 173.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 11.75 million shares worth more than $20.33 million. As of 2024-06-30, BLACKROCK INC. held 10.4236% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 10.6 million shares as of 2024-06-30. The firm’s total holdings are worth over $18.34 million and represent 9.4035% of shares outstanding.
